A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)
In the register
The register attaches this trial to Dutasteride (Avodart / Zagallo) (GSK), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- GlaxoSmithKline
- Participants (registry)
- 153
- Start
- December 2006
- Primary completion
- January 2008
- Study completion
- January 2008
- Last registry update
- August 2018
- Countries
- —
Conditions studied: Alopecia
Interventions: Dutasteride 0.5mg oral tablets
Other trials of Dutasteride (Avodart / Zagallo)
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
- NCT01004809Completed
AVODART® Alopecia Post-marketing Surveillance (PMS)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.